Autres langues Lundbeck Nasdaq Copenhagen

Actions

LUN

DK0061804697

Produits pharmaceutiques

Temps réel estimé Cboe Europe 16:02:33 25/08/2026			Varia. 5j.	Varia. 1 janv.
42,55 ^DKK	+3,78%		+14,93%	+16,99%

24/08	Lundbeck obtient la désignation de médicament orphelin dans l'UE pour un traitement expérimental du syndrome de Cushing	MT
24/08	Lundbeck obtient le statut de médicament orphelin dans l'UE pour l'asedebart	FW

Autres langues

24/08	Lundbeck's Obtains Orphan Designation in EU for Investigational Treatment for Cushing's Syndrome
24/08	European Commission grants orphan designation for Lundbeck's investigational anti-ACTH monoclonal antibody asedebart for Cushing's syndrome of endogenous origin
20/08	Cancer vaccines finally garner the spotlight
19/08	H Lundbeck : Q2 beat, but pipeline execution remains non-negotiable
19/08	Danish Pharma H. Lundbeck Expects No Slowdown for Primary Growth Driver Brands
19/08	H. Lundbeck A/S Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
19/08	H. Lundbeck's Major Shareholder Kicks Off Voluntary Share Exchange Offer
19/08	Lundbeckfond Invest A/S launches voluntary exchange offer for A-shares in H. Lundbeck A/S
19/08	Strong growth from Vyepti[®] and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
11/08	Moberg Pharma Appoints Business, Medical Chiefs
23/07	Lundbeck Receives FDA Fast Track Designation for Lu AH69593, Investigational Orexin 2 Receptor Agonist for Narcolepsy
23/07	Lundbeck Secures US FDA Fast Track Designation for Narcolepsy Drug
23/07	Lundbeck receives FDA Fast Track designation for Lu AH69593, an investigational orexin 2 receptor agonist for narcolepsy
20/07	H. Lundbeck A/S Completes Randomization In DEEp OCEAN Phase III Clinical Trial Evaluating Bexicaserin For Treatment Of Seizures Associated With Developmental And Epileptic Encephalopathies
20/07	Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)
14/07	Where would AI lead Pharma in the long run?
24/06	H. Lundbeck A/S Announces Executive Changes
24/06	Tarek Samad appointed EVP, Head of Research & Development at Lundbeck
24/06	Lundbeck presents new Vyepti® (eptinezumab) and bocunebart migraine portfolio data at EAN 2026
14/06	Lundbeck presents new Phase II asedebart data in Cushing's disease at ENDO 2026
14/06	H. Lundbeck A/S Presents Preliminary Phase II Part A Data for Asedebart in Cushing's Disease
10/06	Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
04/06	H. Lundbeck Presents Positive Phase IIb Data For Bocunebart In Migraine Prevention
04/06	Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress
03/06	Lundbeck Enters Partnership with Cradle for Brain Disorder Therapies